Adverse drug reactions with halogenated anesthetics

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 1, 2008, Pages 158-162

  Kharasch, E D ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LYASE; CHLORODIFLUOROETHENE; CHLOROFLUOROCARBON; CHLOROFLUOROHYDROCARBON; CHLOROTRIFLUOROETHANE; CYTOCHROME P450 2A6; CYTOCHROME P450 2E1; DESFLURANE; DRUG METABOLITE; ENFLURANE; FLUORIDE; HALOTHANE; INHALATION ANESTHETIC AGENT; ISOFLURANE; LYASE; METHOXYFLURANE; SEVOFLURANE; TRIFLUOROACETIC ACID;

ANESTHESIA; ANTIBODY PRODUCTION; ATTRIBUTABLE RISK; CREATININE BLOOD LEVEL; CYTOTOXICITY; DEFLUORINATION; DEHYDRATION; DETOXIFICATION; DRUG DEGRADATION; DRUG DISPOSITION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; EXPERIMENTAL RAT; HEPATITIS; HUMAN; HYPERNATREMIA; IMMUNE RESPONSE; KIDNEY FAILURE; LIVER NECROSIS; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; POLYURIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SULFOXIDATION; UREA NITROGEN BLOOD LEVEL;

ANESTHETICS, INHALATION; HALOTHANE; HUMANS; HYDROCARBONS, HALOGENATED; KIDNEY; LIVER;

EID: 45549106783     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.97     Document Type: Review

References (30)

1. Terrell, R.C. The invention and development of enflurane, isoflurane, sevoflurane, and desflurane. Anesthesiology 108, 531-533 (2008).
2. Bovill, J.G. Inhalation anaesthesia: from diethyl ether to xenon. Handb. Exp. Pharmacol. 182, 121-142 (2008).
3. Ray, D.C. & Drummond, G.B. Halothane hepatitis. Br. J. Anaesth. 67, 84-99 (1991).
4. Kharasch, E.D., Hankins, D.C., Fenstamaker, K. & Cox, K. Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur. J. Clin. Pharmacol. 55, 853-859 (2000).
5. Pohl, L.R., Satoh, H., Christ, D.D. & Kenna, J.G. The immunologic and metabolic basis of drug hypersensitivities. Annu. Rev. Pharmacol. Toxicol. 28, 367-387 (1988).
6. Kharasch, E.D., Hankins, D., Mautz, D. & Thummel, K.E. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347, 1367-1371 (1996).
7. Christ, D.D., Satoh, H., Kenna, J.G. & Pohl, L.R. Potential metabolic basis for enflurane hepatitis and the apparent cross-sensitization between enflurane and halothane. Drug Metab. Dispos. 16, 135-140 (1988).
8. Njoku, D., Laster, M.J., Gong, D.H., Eger E.I. 2nd, Reed, G.F. & Martin, J.L. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: association between protein acylation and hepatic injury. Anesth. Analg. 84, 173-178 (1997).
9. Kharasch, E.D. Biotransformation of sevoflurane. Anesth. Analg. 81, S27-S38 (1995).
10. Harris, J.W. et al. Pentahaloethane-based chlorofluorocarbon substitutes and halothane: Correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation. Chem. Res. Toxicol. 5, 720-725 (1992).
11. Mazze, R.I. Fluorinated anaesthetic nephrotoxicity: an update. Can. Anaesth. Soc. J. 31, S16-S22 (1984).
12. Mazze, R.I. Methoxyflurane revisited: tale of an anesthetic from cradle to grave. Anesthesiology 105, 843-846 (2006).
13. Cousins, M.J. & Mazze, R.I. Methoxyflurane nephrotoxicity. A study of dose response in man. JAMA 225, 1611-1616 (1973).
14. Kharasch, E.D. Sevoflurane and the kidney: a current perspective. Anesth. Clin. North Am. Annu. Anesth. Pharmacol. 1, 205-222 (1996).
15. Mazze, R.I., Woodruff, R.E. & Heerdt, M.E. Isoniazid-induced enflurane defluorination in humans. Anesthesiology 57, 5-8 (1982).
16. Eger E.I. 2nd et al. Dose-related biochemical markers of renal injury after sevoflurane versus desflurane anesthesia in volunteers. Anesth. Analg. 85, 1154-1163 (1997).
17. Spencer, E.M., Willatts, S.M. & Prys-Roberts, C. Plasma inorganic fluoride concentrations during and after prolonged (greater than 24 h) isoflurane sedation: effect on renal function. Anesth. Analg. 73, 731-737 (1991).
18. Murray, J.M. & Trinick, T.R. Plasma fluoride concentrations during and after prolonged anesthesia: a comparison of halothane and isoflurane. Anesth. Analg. 74, 236-240 (1992).
19. Kharasch, E.D., Schroeder, J.L., Liggitt, H.D., Park, S.B., Whittington, D. & Sheffels, P. New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development I. Identification of the nephrotoxic metabolic pathway. Anesthesiology 105, 726-736 (2006).
20. Warren, B.K., Mozaffari, M.S. & Patel, C. Effects of inorganic fluoride on renal excretion of fluid and sodium in diabetic rats. Methods Find. Exp. Clin. Pharmacol. 20, 761-769 (1998).
21. Kharasch, E.D., Hankins, D.C. & Thummel, K.E. Human kidney methoxyflurane and sevoflurane metabolism: intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology 82, 689-699 (1995).
22. Kharasch, E.D., Schroeder, J.L., Liggitt, H.D., Ensign, D. & Whittington, D. New insights into the mechanism of methoxyflurane nephrotoxicity and implications for anesthetic development (part 2): identification of the nephrotoxic metabolites. Anesthesiology 105, 737-745 (2006).
23. Anders, M.W. Formation and toxicity of anesthetic degradation products. Annu. Rev. Pharmacol. Toxicol. 45, 147-176 (2005).
24. Kharasch, E.D., Schroeder, J.L., Sheffels, P. & Liggitt, H.D. Influence of sevoflurane on the metabolism and renal effects of compound A in rats. Anesthesiology 103, 1183-1188 (2005).
25. Kharasch, E.D. & Jubert, C. Compound A uptake and metabolism to mercapturic acids and 3,3,3-trifluoro-2-fluoromethoxypropanoic acid during low-flow sevoflurane anesthesia: biomarkers for exposure, risk assessment, and interspecies comparison. Anesthesiology 91, 1267-1278 (1999).
26. Lash, L.H., Fisher, J.W., Lipscomb, J.C. & Parker, J.C. Metabolism of trichloroethylene. Environ. Health Perspect. 108 (suppl. 2), 177-200 (2000).
27. Assessing the Human Health Risks of Trichloroethylene: Key Scientific Issues (National Academies Press, Washington, DC, 2006).
28. Baxter, P.J., Garton, K. & Kharasch, E.D. Mechanistic aspects of carbon monoxide formation from volatile anesthetics. Anesthesiology 89, 929-941 (1998).
29. Woehlck, H.J., Mei, D., Dunning, M.B. 3rd & Ruiz, F. Mathematical modeling of carbon monoxide exposures from anesthetic breakdown. Anesthesiology 94, 457-460 (2001).
30. Spracklin, D.K., Hankins, D.C., Fisher, J.M., Thummel, K.E. & Kharasch, E.D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 281, 400-411 (1997).